271 related articles for article (PubMed ID: 24553861)
1. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
2. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.
Hirai H; Tada Y; Nakaguro M; Kawakita D; Sato Y; Shimura T; Tsukahara K; Kano S; Ozawa H; Okami K; Sato Y; Fushimi C; Shimizu A; Okamoto I; Takase S; Okada T; Sato H; Imanishi Y; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Saigusa N; Takahashi H; Ando M; Urano M; Hanazawa T; Nagao T
Virchows Arch; 2020 Aug; 477(2):291-299. PubMed ID: 32103349
[TBL] [Abstract][Full Text] [Related]
4. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
5. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
[TBL] [Abstract][Full Text] [Related]
6. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
9. The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
Urano M; Hirai H; Tada Y; Kawakita D; Shimura T; Tsukahara K; Kano S; Ozawa H; Okami K; Sato Y; Fushimi C; Shimizu A; Takase S; Okada T; Sato H; Imanishi Y; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Sato Y; Saigusa N; Nakaguro M; Hanazawa T; Nagao T
Histopathology; 2018 Dec; 73(6):943-952. PubMed ID: 29993139
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
11. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcome analysis of salivary duct carcinoma.
Han MW; Roh JL; Choi SH; Nam SY; Lee HJ; Cho KJ; Lee SW; Kim SY
Auris Nasus Larynx; 2015 Dec; 42(6):472-7. PubMed ID: 26028371
[TBL] [Abstract][Full Text] [Related]
13. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
14. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
15. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma.
Fan CY; Melhem MF; Hosal AS; Grandis JR; Barnes EL
Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1075-9. PubMed ID: 11556855
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
17. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
18. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
19. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
[TBL] [Abstract][Full Text] [Related]
20. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
